GITNUXREPORT 2025

Sstr Statistics

SSTR imaging detects neuroendocrine tumors with over 90% sensitivity and accuracy.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

Advances in SSTR antagonist development have demonstrated up to 70% higher tumor binding affinity than previous agonists, increasing diagnostic accuracy

Statistic 2

Around 80% of neuroendocrine tumors are detectable using somatostatin receptor imaging

Statistic 3

The sensitivity of SSTR PET imaging in neuroendocrine tumors exceeds 90%

Statistic 4

(68)Ga-DOTATATE PET/CT has a sensitivity of approximately 93% for detecting neuroendocrine tumors

Statistic 5

SSTR antagonists show higher tumor uptake than agonists in preclinical models, potentially improving imaging sensitivity

Statistic 6

SSTR imaging plays a crucial role in the staging of neuroendocrine tumors, influencing treatment decisions in over 85% of cases

Statistic 7

The half-life of (68)Ga used in PET imaging is approximately 68 minutes, facilitating high-quality imaging within a short window

Statistic 8

SSTRPET/CT has a detection accuracy rate of over 95% for residual or recurrent neuroendocrine tumors

Statistic 9

SSTR-based imaging is effective in detecting primary neuroendocrine tumors in approximately 60-70% of cases

Statistic 10

The development of SSTR antagonists has led to imaging agents with up to 50% higher tumor uptake compared to agonists, improving detection sensitivity

Statistic 11

Approximately 25% of patients with neuroendocrine tumors have metastases at diagnosis, emphasizing the importance of SSTR imaging for comprehensive staging

Statistic 12

The detection rate of SSTR PET imaging in well-differentiated neuroendocrine tumors exceeds 85%, depending on tumor location and receptor density

Statistic 13

(68)Ga-SSTR PET/CT has an accuracy rate of approximately 95% in detecting neuroendocrine tumor lesions

Statistic 14

SSTR-targeted imaging agents like (68)Ga-DOTATATE have a spatial resolution of approximately 4-5 mm in PET scans, aiding in precise tumor localization

Statistic 15

In clinical trials, SSTR PET imaging led to changes in management plans for roughly 30% of patients with neuroendocrine tumors

Statistic 16

Imaging with SSTR-targeted agents can distinguish between active disease and necrosis, aiding in therapy planning

Statistic 17

(68)Ga radiotracers are produced via generator systems, simplifying the logistics for widespread clinical use

Statistic 18

The use of SSTR imaging can identify occult primary tumors in cases where initial imaging is inconclusive, improving diagnostic yield by approximately 15%

Statistic 19

The global market for somatostatin receptor imaging agents is projected to reach $1.2 billion by 2025

Statistic 20

SSTR (Somatostatin Receptor) is overexpressed in approximately 70% of neuroendocrine tumors

Statistic 21

SSTR expression levels correlate with tumor grade in neuroendocrine tumors, with higher expression in lower-grade tumors

Statistic 22

SSTR2 is the most commonly overexpressed receptor subtype in neuroendocrine tumors

Statistic 23

Approximately 60% of gastrointestinal neuroendocrine tumors express SSTR2

Statistic 24

SSTR expression can be heterogeneous within the same tumor, complicating targeted imaging and therapy

Statistic 25

The expression of SSTR2 can be modulated by cytokines and other tumor microenvironment factors, impacting imaging and treatment response

Statistic 26

SSTR expression is retained in most neuroendocrine tumor recurrences, which helps guide repeat imaging and therapy

Statistic 27

The expression of SSTR can be used to predict response to somatostatin analog therapy, with higher receptor expression linked to better outcomes

Statistic 28

SSTR2 overexpression has been associated with lower tumor grade and better prognosis in neuroendocrine tumors

Statistic 29

Conversely, SSTR-negative tumors are often more aggressive and have poorer prognosis

Statistic 30

SSTR expression is also found in some non-neuroendocrine tumors, such as meningiomas and paragangliomas, supporting broader diagnostic applications

Statistic 31

Approximately 65% of patients with neuroendocrine tumors express SSTR3, though it is less commonly targeted than SSTR2

Statistic 32

The use of SSTR-targeted therapies improved progression-free survival in patients with neuroendocrine tumors by about 20-30%

Statistic 33

SSTR-targeted radionuclide therapy, such as Lutetium-177-DOTATATE, has an overall response rate of around 30-40% in metastatic neuroendocrine tumors

Statistic 34

Over 80% of patients with neuroendocrine tumors treated with SSTR-targeted radionuclide therapy experience symptom relief

Statistic 35

The half-life of (177)Lu is 6.65 days, suitable for targeted radionuclide therapy, enabling sustained tumor irradiation

Statistic 36

The use of (177)Lu-DOTATATE therapy has been shown to improve progression-free survival by about 14 months in some neuroendocrine tumor patients

Statistic 37

SSTR-targeted radionuclide therapy has been associated with manageable side effects, with fatigue, nausea, and mild hematological toxicity being the most common

Slide 1 of 37

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

SSTR (Somatostatin Receptor) is overexpressed in approximately 70% of neuroendocrine tumors
Around 80% of neuroendocrine tumors are detectable using somatostatin receptor imaging
The sensitivity of SSTR PET imaging in neuroendocrine tumors exceeds 90%
SSTR expression levels correlate with tumor grade in neuroendocrine tumors, with higher expression in lower-grade tumors
(68)Ga-DOTATATE PET/CT has a sensitivity of approximately 93% for detecting neuroendocrine tumors
SSTR2 is the most commonly overexpressed receptor subtype in neuroendocrine tumors
The use of SSTR-targeted therapies improved progression-free survival in patients with neuroendocrine tumors by about 20-30%
Approximately 60% of gastrointestinal neuroendocrine tumors express SSTR2
SSTR antagonists show higher tumor uptake than agonists in preclinical models, potentially improving imaging sensitivity
The global market for somatostatin receptor imaging agents is projected to reach $1.2 billion by 2025
SSTR imaging plays a crucial role in the staging of neuroendocrine tumors, influencing treatment decisions in over 85% of cases
The half-life of (68)Ga used in PET imaging is approximately 68 minutes, facilitating high-quality imaging within a short window
SSTR-targeted radionuclide therapy, such as Lutetium-177-DOTATATE, has an overall response rate of around 30-40% in metastatic neuroendocrine tumors

Did you know that somatostatin receptor (SSTR) overexpression occurs in about 70% of neuroendocrine tumors, enabling highly sensitive imaging and targeted therapies that significantly improve diagnosis and patient outcomes?

Advancements and Research Developments

Advances in SSTR antagonist development have demonstrated up to 70% higher tumor binding affinity than previous agonists, increasing diagnostic accuracy

Advancements and Research Developments Interpretation

With the advent of SSTR antagonists boasting up to 70% greater tumor binding affinity, we’re not just improving diagnostics—we're essentially giving our imaging techniques a sharper eye in the fight against cancer.

Diagnostics and Imaging Techniques

Around 80% of neuroendocrine tumors are detectable using somatostatin receptor imaging
The sensitivity of SSTR PET imaging in neuroendocrine tumors exceeds 90%
(68)Ga-DOTATATE PET/CT has a sensitivity of approximately 93% for detecting neuroendocrine tumors
SSTR antagonists show higher tumor uptake than agonists in preclinical models, potentially improving imaging sensitivity
SSTR imaging plays a crucial role in the staging of neuroendocrine tumors, influencing treatment decisions in over 85% of cases
The half-life of (68)Ga used in PET imaging is approximately 68 minutes, facilitating high-quality imaging within a short window
SSTRPET/CT has a detection accuracy rate of over 95% for residual or recurrent neuroendocrine tumors
SSTR-based imaging is effective in detecting primary neuroendocrine tumors in approximately 60-70% of cases
The development of SSTR antagonists has led to imaging agents with up to 50% higher tumor uptake compared to agonists, improving detection sensitivity
Approximately 25% of patients with neuroendocrine tumors have metastases at diagnosis, emphasizing the importance of SSTR imaging for comprehensive staging
The detection rate of SSTR PET imaging in well-differentiated neuroendocrine tumors exceeds 85%, depending on tumor location and receptor density
(68)Ga-SSTR PET/CT has an accuracy rate of approximately 95% in detecting neuroendocrine tumor lesions
SSTR-targeted imaging agents like (68)Ga-DOTATATE have a spatial resolution of approximately 4-5 mm in PET scans, aiding in precise tumor localization
In clinical trials, SSTR PET imaging led to changes in management plans for roughly 30% of patients with neuroendocrine tumors
Imaging with SSTR-targeted agents can distinguish between active disease and necrosis, aiding in therapy planning
(68)Ga radiotracers are produced via generator systems, simplifying the logistics for widespread clinical use
The use of SSTR imaging can identify occult primary tumors in cases where initial imaging is inconclusive, improving diagnostic yield by approximately 15%

Diagnostics and Imaging Techniques Interpretation

With over 90% sensitivity and a 95% accuracy rate, somatostatin receptor imaging boldly outperforms traditional methods in detecting neuroendocrine tumors—proving that when it comes to precise tumor detection, perhaps it's time to put the receptor in charge.

Market and Industry Insights

The global market for somatostatin receptor imaging agents is projected to reach $1.2 billion by 2025

Market and Industry Insights Interpretation

With the global somatostatin receptor imaging agents market expected to hit $1.2 billion by 2025, it seems the world is increasingly betting on pinpointing tumors — proving that sometimes, precise science is truly a billion-dollar question.

Receptor Expression and Biological Characteristics

SSTR (Somatostatin Receptor) is overexpressed in approximately 70% of neuroendocrine tumors
SSTR expression levels correlate with tumor grade in neuroendocrine tumors, with higher expression in lower-grade tumors
SSTR2 is the most commonly overexpressed receptor subtype in neuroendocrine tumors
Approximately 60% of gastrointestinal neuroendocrine tumors express SSTR2
SSTR expression can be heterogeneous within the same tumor, complicating targeted imaging and therapy
The expression of SSTR2 can be modulated by cytokines and other tumor microenvironment factors, impacting imaging and treatment response
SSTR expression is retained in most neuroendocrine tumor recurrences, which helps guide repeat imaging and therapy
The expression of SSTR can be used to predict response to somatostatin analog therapy, with higher receptor expression linked to better outcomes
SSTR2 overexpression has been associated with lower tumor grade and better prognosis in neuroendocrine tumors
Conversely, SSTR-negative tumors are often more aggressive and have poorer prognosis
SSTR expression is also found in some non-neuroendocrine tumors, such as meningiomas and paragangliomas, supporting broader diagnostic applications
Approximately 65% of patients with neuroendocrine tumors express SSTR3, though it is less commonly targeted than SSTR2

Receptor Expression and Biological Characteristics Interpretation

While over 70% of neuroendocrine tumors overexpress SSTR—particularly the ubiquitous SSTR2—this receptor's heterogeneity and microenvironment influences, along with its retention in recurrences, underscore its value as a double-edged biomarker: guiding targeted imaging and therapy, yet reminding clinicians that tumor grade and prognosis remain intricately linked to its variable expression.

Therapeutic Applications and Treatments

The use of SSTR-targeted therapies improved progression-free survival in patients with neuroendocrine tumors by about 20-30%
SSTR-targeted radionuclide therapy, such as Lutetium-177-DOTATATE, has an overall response rate of around 30-40% in metastatic neuroendocrine tumors
Over 80% of patients with neuroendocrine tumors treated with SSTR-targeted radionuclide therapy experience symptom relief
The half-life of (177)Lu is 6.65 days, suitable for targeted radionuclide therapy, enabling sustained tumor irradiation
The use of (177)Lu-DOTATATE therapy has been shown to improve progression-free survival by about 14 months in some neuroendocrine tumor patients
SSTR-targeted radionuclide therapy has been associated with manageable side effects, with fatigue, nausea, and mild hematological toxicity being the most common

Therapeutic Applications and Treatments Interpretation

SSTR-targeted radionuclide therapy, with its notable boost in progression-free survival, nearly one-third response rate, and over 80% symptom relief, proves to be a potent yet manageable weapon in the neuroendocrine tumor arsenal, with its radioactive charm set to last roughly two weeks.